The Tom1 gene was initially identified as a specific target of retroviral oncogene v-Myb.
The Tom1 gene was initially identified as a specific target of retroviral oncogene v-Myb. 1) This protein has an N-terminal VHS domain 2) followed by a short GAT domain.
3) The crystal structures of the VHS domains of Tom1, 4) Hrs, 5) and GGA proteins 6, 7) have been determined. Although their global structures are similar, the VHS domains of GGA1 and GGA3, but not those of Tom1 and Hrs, have a specific recognition pocket for the mannose-6-phosphate receptor. 6, 7) Recently, the crystal structure of the GAT domain of GGA1 has been reported, [8] [9] [10] but its helical extension, which is indispensable for the association of GGA1 with ARF, is not conserved in the GAT domain of Tom1. Thus, the structurefunction relationships in the VHS and GAT domains of GGA proteins have been extensively elucidated, but those of Tom1 have not yet been determined. To investigate the function of Tom1, we previously carried out yeast two-hybrid screening using Tom1 as bait and found that Tollip is a Tom1-binding protein.
11)
The adaptor protein Tollip was identified as an intermediate in IL-1-dependent signaling.
12) IL-1 plays a central role in mediating a variety of inflammatory responses.
13) The binding of IL-1 to the type I IL-1 receptor (IL-1RI) and the subsequent recruitment of the accessory protein IL-1RAcp result in their close spatial association, which allows the recruitment of the adaptor protein MyD88 and the IL-1R-associated-kinase (IRAK). In resting cells, Tollip forms a complex with IRAK and inhibits IL-1-induced signaling by blocking IRAK phosphorylation. 12) In response to IL-1 signaling, IRAK becomes rapidly phosphorylated, dissociates from the receptor complex, and then associates with the downstream adaptor proteins such as TNF-associated factor 6 (TRAF6). The IL-1-induced signaling pathway bifurcates at TRAF6, 14, 15) leading to the activation of the IkB kinase (IKK) complex and mitogen-activated protein kinases. These former and latter pathways are central to activation of the transcription factors nuclear factor (NF)-kB and AP-1, respectively. 16, 17) In this study, we found that Tom1 inhibits the IL-1b-induced signaling pathway that leads to the activation of NFkB and AP-1, as Tollip does. 12) On the other hand, in contrast to the action of Tollip, 12) Tom1 was found to inhibit the TNFa-induced signaling pathway, which also leads to the activation of NF-kB and AP-1. 18, 19) To our knowledge, this is the first report of a common negative regulator of signaling pathways induced by IL-1b and TNF-a.
MATERIALS AND METHODS

Cell Culture and Transfection
Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen). Transfection was performed using FuGene6 (Roche) according to the manufacturer's protocol.
Plasmid Construction The open-reading frames of mouse Tom1, Tollip, and IL-1RI, all containing EcoRI and SalI sites, were amplified by PCR using the respective primers. The PCR fragments were subcloned into the pGEM-T vector (Promega). All of the truncated mutants were generated by PCR and subcloned. All constructs were verified by DNA sequencing. To generate the expression plasmids, the respective PCR fragments that had been digested with EcoRI and SalI were inserted into the EcoRI and SalI sites of mammalian expression vectors, pSF1 11) and pCI-neo-T7 (Promega).
Establishment of IL-1RI Stable Cell Line HEK293 cells were transfected with the pCI-neo-T7-IL-1RI plasmid and cultured as described above. After 2 d, the cells were cultivated in a selection medium containing 750 mg/ml geneticin (Invitrogen) for 10 d, and individual clones were isolated. One clone expressing IL-1RI, designated HEK293-IL-1RI, was selected from 24 cell lines derived from the isolated clones by a reporter gene assay and was then maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum and 750 mg/ml geneticin.
Reporter Gene Assay HEK293 or HEK293-IL-1RI cells were transfected with the pNF-kB-Luc or pAP-1-Luc reporter plasmid (Clontech) together with the pSF1-Tom1 full-length or pSF1-Tom1 mutant plasmid. The total amount of plasmids was adjusted with the empty vector pSF1. Forty hours after transfection, cells were stimulated with 10 ng/ml IL-1b (Roche) or TNF-a (Sigma) for 6 h. Cells were then lysed and the lysate was subjected to a luciferase assay using a Dual-Luciferase Reporter Assay System (Promega). Each reporter gene activity was normalized by protein concentration of the cell lysate.
RESULTS AND DISCUSSION
The Tom1 protein has a VHS domain in the N-terminal part and a GAT domain in a central part. By yeast two-hybrid screening, we identified Tollip, ubiquitin and clathrin as Tom1-binding proteins, and Tom1 was found to bind with Tollip through its GAT domain. 11) Since Tollip has been reported to impair IL-1b-induced activation of NF-kB and cjun N-terminal kinase (JNK), 12) we first determined whether Tom1 also plays a negative role in IL-1b-dependent signaling. We established a stable cell line, HEK293-IL-1RI, and the cells were transfected with increasing amounts of Tom1 full-length expression plasmid together with either NF-kB or AP-1 luciferase reporter plasmid (Fig. 1) . Luciferase activity was measured after stimulation with IL-1b for 6 h. In response to IL-1b stimulation, NF-kB (Fig. 1A) or AP-1 (Fig.  1B) was activated in mock-transfected cells, while overexpression of Tom1 alone failed to induce activation of NF-kB or AP-1. On the other hand, Tom1 was found to inhibit IL1b-induced activation of NF-kB (Fig. 1A) or AP-1 (Fig. 1B) in a dose-dependent manner, suggesting that Tom1 is a negative regulator of the IL-1b-induced signaling pathway leading to activation of NF-kB and AP-1. This IL-1b-induced signaling pathway bifurcates at TRAF6, leading to activation of both NF-kB and AP-1 through distinct pathways. 14, 15) Thus, it is possible that a target of Tom1 is a putative common mediator functioning at or upstream of the bifurcate point, i.e., TRAF6.
Since overexpression of Tollip fails to inhibit TNF-a-induced activation of NF-kB and JNK, 12) we next carried out the same reporter gene assay on TNF-a stimulation as that on IL-1b stimulation described above. In contrast to the action of Tollip, overexpression of Tom1 suppressed TNF-ainduced activation of NF-kB ( Fig. 2A) and AP-1 (Fig. 2B) . Since the TNF-a-induced signaling pathway bifurcates at TRAF2, leading to activation of both NF-kB and AP-1 through distinct pathways, 18, 19) it is possible that a target of Tom1 is a common mediator functioning at or upstream of the bifurcate point, i.e., TRAF2. Collectively, the data in Figs. 1 and 2 , showing that overexpression of Tom1 suppresses the activation of two transcription factors NF-kB and AP-1, induced by IL-1b or TNF-a, suggest that Tom1 is a common suppressor in both IL-1b-and TNF-a-dependent pathways. It has been reported that IKK is a common mediator in the NF-kB pathways induced by both IL-1b and TNFa, 19) while JNK or MEKKK is a common mediator in the AP-1 pathways induced by both IL-1b and TNF-a. 15, 18) However, the presence of a common mediator functioning in the four IL-1b and TNF-a-induced signaling pathways has not been reported hitherto.
To determine the domain of Tom1 that is indispensable for its negative regulation of IL-1b-and TNF-a-induced signaling pathways, we carried out reporter gene assays using various truncated mutants of Tom1 (Fig. 3A) . The C-terminallytruncated Tom1 mutant, Tom1 (1-310), as well as Tom1 full length, Tom1 (1-492), efficiently suppressed activation of both NF-kB (Figs. 3B, D) and AP-1 (Figs. 3C, E) , induced by either IL-1b (Figs. 3B, C) or TNF-a (Figs. 3D, E) , and the Tom1 mutant with deletion of the GAT domain, Tom1 (D181-310), showed moderate but substantial suppressive activity in either case. In contrast, the Tom1 mutant with deletion of the VHS domain, Tom1 (181-492), showed little suppressive activity in either case. These results indicate that the VHS domain of Tom1 is indispensable for its negative regulation of both IL-1b-and TNF-a-induced signaling pathways.
We previously reported that the GAT domain of Tom1 is required for interaction between Tom1 and Tollip.
11) The present result showing that the Tom1 mutant with deletion of the GAT domain shows a substantial suppressive effect on the IL-1b-and TNF-a-induced signaling pathways implies that Tom1 has a suppressive activity independent of Tollip.
In conclusion, we demonstrated that the Tom1 protein is a common negative regulator of the IL-1b-and TNF-a-induced signaling pathways. Furthermore, it was found that the VHS domain of Tom1 is essential for its suppressive effects on two cytokine-induced signaling pathways. This finding is the first report on the functioning of the VHS domain in Tom1, implying that a putative protein capable of binding with the VHS domain of Tom1 plays a common role in the HEK293 cells, transfected as described in Fig. 1 , were stimulated with 10 ng/ml TNF-a (shaded columns) for 6 h or were left untreated (white columns), and reporter gene assays were carried out as described in Fig. 1 .
IL-1b-and TNF-a-induced signaling pathways. A search for the target of Tom1 is necessary to determine the mechanism underlying the suppression of the cytokine-dependent signaling by Tom1. Vol. 27, No. 4 Figs. 1  and 2 , respectively, except for the expression plasmids (0.375 mg) containing Tom1 deletion mutants (A), were stimulated with 10 ng/ml IL-1b (B, C; closed columns) and TNF-a (D, E: shaded columns), respectively, for 6 h or were left untreated (white columns), and reporter gene assays were carried out as described in Fig. 1 .
